Article info

PDF
Letter
Phase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2

Authors

  1. Correspondence to Professor C Oliver Hanemann, Peninsula Clinical Trials Unit, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth PL6 8BU, UK; Oliver.Hanemann{at}plymouth.ac.uk
View Full Text

Citation

Ammoun S, Evans DG, Hilton DA, et al
Phase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2

Publication history

  • Received September 27, 2018
  • Revised January 9, 2019
  • Accepted January 16, 2019
  • First published February 4, 2019.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.